Showing 751-760 of 3453 results for "".
Unwinding Psoriasis Comorbidities
https://practicaldermatology.com/topics/psoriasis/unwinding-psoriasis-comorbidities/18936/Ronald Prussick, MD assesses the state of psoriasis treatment, with a particular focus on comorbidities. He also sums up new pivotal data on comborbitities that may shift the treatment spectrum.Planning a Comeback
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/planning-a-comeback/23300/CSF Faculty members open up about how COVID-19 impacted their practices and what they did about it.Scientifically Speaking: The Truth About Skincare
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-the-truth-about-skincare/19876/From workhorse ingredients like antioxidants and retinol to newer molecules that address pigmentation and aging, there is a lot of noise in the skincare marketplace. And that's without talking about "natural" formulations. Joel L. Cohen, MD gets to the heart of the science, in a conversation with DeThe Case for JAK Inhibitors to Treat AD
https://practicaldermatology.com/topics/atopic-dermatitis/case-jak-inhibitors-treat-ad/27109/E. James Song, MD, FAAD, Director of Clinical Research and Co-Chief Medical Officer for Frontier Dermatology, discusses his presentation “JAK Inhibitors in Atopic Dermatitis” from the 2024 American Academy of Dermatology (AAD) Innovation Academy.Mentors in Dermatology
https://practicaldermatology.com/topics/practice-management/mentors-in-dermatology/18719/Neal Bhatia, MD sat down with one of his mentees, Al Damavandy, MD, to discuss what makes a great mentee-mentor relationship and how both parties can benefit. Dr. Damavandy, now a practicing Mohs Surgeon and Dermatologist, shared tips for how to find the right mentor and what he learned from his menThe Resurgence of Ablative Devices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-resurgence-of-ablative-devices/18620/E. Victor Ross, MD, talks to host Joel L. Cohen, MD about the resurgence of traditional ablative devices. Dr. Ross says he never abandoned full-face CO2 resurfacing, but explains the key is to titrate the settings down—doing confluent 100 percent coverage but low-depth one pass on the forehead and cWhat is the most important thing you do every morning?
https://practicaldermatology.com/topics/practice-management/what-is-the-most-important-thing-you-do-every-morning/18566/Adam Friedman, MD shares what he does every morning to set the tone and mentally prepare for the day. Watch other PD Asks videos with Adam Friedman, MD, FAAD: In a movie about your practice, who would play you? What is the best "prop" or fixture in your exam rooms that facilitates patient interaLex Icon: Lexington's Randy Waldman Speaks the Language of Successful Site Planning with Joel L. Cohen
https://practicaldermatology.com/topics/practice-management/lex-icon-lexington-s-randy-waldman-speaks-the-language-of-successful-site-planning-with-joel-l-cohen--ovevisoh/18901/How do you plan a brand new, state-of-the art surgical and clinical space that's accessible yet feels exclusive? Should you rent or buy? How do you balance your time? S. Randolph Waldman, MD answers these questions and more from series host Joel L. Cohen, MD in this edition of Best Practices.Journal Club: A Comprehensive Update
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-a-comprehensive-update/32402/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses the recent Lancet article "Atopic Dermatitis" with primary author Emma Guttman, MD, PhD. Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):583-596. doi: 10.1016/S0140-6736(24)0Diverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into why